Literature DB >> 16585442

Psychological responses to continuous terror: a study of two communities in Israel.

Arieh Y Shalev1, Rivka Tuval, Sarah Frenkiel-Fishman, Hilit Hadar, Spencer Eth.   

Abstract

OBJECTIVE: The authors evaluated psychological responses to continuous terror.
METHOD: Data were collected after 10 months of escalating hostilities against civilians in Israel. The study's participants were randomly selected adults living in two suburbs of Jerusalem, one frequently and directly exposed to acts of terrorism (N=167) and the other indirectly exposed (N=89). Participants provided information about exposure to terror-related incidents, disruption of daily living, symptoms of posttraumatic stress disorder (PTSD), and general distress (assessed with the Brief Symptom Inventory).
RESULTS: Residents of the directly exposed community reported more frequent exposure to terror and deeper disruption of daily living. Notwithstanding, the directly and indirectly exposed groups reported comparable rates of PTSD and similar levels of symptoms: 26.95% of the directly exposed group and 21.35% of the indirectly exposed group met DSM-IV PTSD symptom criteria (criteria B through D), and about one-third of those with PTSD symptoms (35.7% in the directly exposed group and 31.5% in the indirectly exposed group) reported significant distress and dysfunction. Subjects who did not meet PTSD symptom criteria had very low levels of PTSD symptoms, and their Brief Symptom Inventory scores were within population norms. Exposure and disruption of daily living contributed to PTSD symptoms in the directly exposed group. Disruption of daily routines contributed to Brief Symptom Inventory scores in both groups.
CONCLUSIONS: Continuous terror created similar distress in proximal and remote communities. Exposure to discrete events was not a necessary mediator of terror threat. A subgroup of those exposed developed serious symptoms, whereas others were surprisingly resilient. Disruption of daily routines was a major secondary stressor.

Entities:  

Mesh:

Year:  2006        PMID: 16585442     DOI: 10.1176/ajp.2006.163.4.667

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   19.242


  7 in total

1.  Characteristics of calls to the Israeli hotline during the Intifada.

Authors:  Itzhak Gilat; Yael Latzer
Journal:  Community Ment Health J       Date:  2007-05-21

2.  Trajectories of resilience, resistance, and distress during ongoing terrorism: the case of Jews and Arabs in Israel.

Authors:  Stevan E Hobfoll; Patrick A Palmieri; Robert J Johnson; Daphna Canetti-Nisim; Brian J Hall; Sandro Galea
Journal:  J Consult Clin Psychol       Date:  2009-02

3.  Psychotropic drug use in Israel: results from the national health survey.

Authors:  Alexander Grinshpoon; Eli Marom; Abraham Weizman; Alexander M Ponizovsky
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

4.  The psychological impact of the Israel-Hezbollah War on Jews and Arabs in Israel: the impact of risk and resilience factors.

Authors:  Patrick A Palmieri; Daphna Canetti-Nisim; Sandro Galea; Robert J Johnson; Stevan E Hobfoll
Journal:  Soc Sci Med       Date:  2008-07-28       Impact factor: 4.634

5.  The differential impact of terrorism on two Israeli communities.

Authors:  Nathan R Stein; Yonit Schorr; Lillian Krantz; Benjamin D Dickstein; Zahava Solomon; Danny Horesh; Brett T Litz
Journal:  Am J Orthopsychiatry       Date:  2013-10

6.  Traumatic events and their relative PTSD burden in Northern Ireland: a consideration of the impact of the 'Troubles'.

Authors:  Finola Ferry; Brendan Bunting; Samuel Murphy; Siobhan O'Neill; Dan Stein; Karestan Koenen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-03       Impact factor: 4.328

7.  Mental health and resiliency following 44 months of terrorism: a survey of an Israeli national representative sample.

Authors:  Avi Bleich; Marc Gelkopf; Yuval Melamed; Zahava Solomon
Journal:  BMC Med       Date:  2006-08-27       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.